- 1、本文档共67页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* * * * * HBeAg, hepatitis B e antigen; LAM, lamivudine; LdT, telbivudine; PCR, polymerase chain reaction; PegIFN, peginterferon; QL, quantification limit. This slide shows that early and profound suppression of viral replication is predictive of a greater sustained response. On the Y axis is the percentage of patients who are PCR negative or HBV DNA undetectable at follow?up. The X axis is divided into 3 parts. The left-most part of the graph represents HBeAg-negative patients undergoing 72 weeks of peginterferon alfa-2a. This part of the graphic shows that HBV DNA level at the early time point of 12 weeks of treatment is strongly predictive of sustained PCR negativity at follow-up. Sixty one percent of patients with HBV DNA 400?copies/mL ( 80 IU/mL) at Week?12 maintained PCR negativity at the follow?up period, but only 31% of the patients with a HBV DNA level 400?copies/mL at Week 12 were HBV DNA undetectable at follow-up. The middle part of the X axis shows data from HBeAg-positive patients undergoing 1 year of lamivudine treatment. Of the patients who were undetectable for HBV DNA at 6 months, 84% maintain undetectability over the follow?up period. On the other hand, only 20% of the patients who had detectable HBV DNA at 6 months achieved HBV DNA negativity over the follow?up period. On the right side of the slide is data from HBeAg-positive patients on 1 year of telbivudine treatment. Of those patients who achieved PCR negativity at 6 months, 95% maintained PCR negativity at the end of 1 year, but only 33% of patients who had a detectable HBV DNA at 6 months achieved PCR negativity at the end of 1 year. For more information, go online to: /Hepatitis/Conference%20Coverage/Vienna%202006/Tracks/HBV/Capsules/51.aspx * * * 使用贺普丁优化方案的临床疗效如何呢?我们来看一项研究。 对74名接受拉米夫定100毫克每天的HBeAg阳性慢乙肝患者持续5年的研究显示,在24周达到完全病毒学应答(HBV DNA水平103拷贝/毫升)的情况下,治疗5年后, 80%患者HBV DNA水平103拷贝/毫升,90%患者HBeAg血清转换,100%ALT复常; 90% 的血清转换率,意味着90%的患者有停药的可能性,这对慢乙肝患者达到初步的治疗至关重要。 * * * 对于应答不佳的管理,路线图中已经明确推荐加用无交叉耐药的
您可能关注的文档
- 论正当防卫的几个问题 毕业论文.doc
- 论中西方古代建筑艺术差异.doc
- 论中小学管弦乐队的组织与训练.doc
- 罗坑学校仪器功能室设备采购项目用户需求书.doc
- 逻辑推理笔记.doc
- 洛南县西街小学学生综合素质评价方案.doc
- 骆中学党务政务公开工作实施方案.doc
- 旅行社会计实验报告.doc
- 旅行社聘用导游劳务合同.doc
- 旅游地产青岛海泉湾温泉度假项目策划报告(阿特金斯).ppt
- 4.1我国的个人收入分配(教材解读)-【省心备课】2022-2023学年高一政治高效课堂精品课件+教材解读+课堂随练(统编版必修2).docx
- 中国国内贸易发展的影响因素及对策研究-SWOT分析.docx
- 发展我国电子商务需迫切解决的问题电商论文.docx
- 远程教育:产业性质与市场机制.docx
- 交互设计在工业设计中的应用研究.docx
- 中国医药行业营业收入、利润额呈上升态势药企亏损额同比下降.docx
- 关于房屋建筑施工管理优化策略的探究吴浩松.docx
- 中外运京津冀运力现状、问题与对策分析.docx
- 火电厂集控运行的危险点预控朱利刚.docx
- 信息化教学在影视后期制作(AfterEffects)课程中的应用研究.docx
文档评论(0)